Barclays strategists expect “disruption into a number of industries,” thanks to drugs like Novo Nordisk’s Ozempic and Wegovy. Read More
We współpracy z: https://fortune.com/2023/10/04/weight-loss-drugs-ozempic-wegovy-novo-nordisk-barclays-bank-short-junk-food-stocks/